Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2002

View Archived Issues

Integrin antagonists in early development at Bayer

Neuropeptide Y ligands identified at Servier

Novel reverse transcriptase inhibitors presented by Roche

Bicyclic heterocycles for pain and other uses

Pierre Fabre presents new protein prenyltransferase inhibitors

Antimicrobial erythromycins identified at Hokuriku Seiyaku

Coenzyme A-peptide conjugates for use in cancer

Irofulven plus Xeloda evaluated in phase I trial in advanced solid tumors

Angiostatin-AAV reduces tumor burden and increases survival in preclinical trials

CAI resistance proteins available for licensing from NIH

Methods for enhanced distribution of therapeutic agents after local delivery available from NIH

Calpain inhibition may limit cardiac ischemia-reperfusion damage

Liposome encapsulation of known anticancer drugs improves tolerance, pharmacokinetics

Clinically significant P-gp inhibition obtained in AML patients with zosuquidar

Lofexidine is safe and attenuates withdrawal signs during opiate detoxification

Oncolytic adenovirus construct for intratumoral delivery characterized at ASGT meeting

Broad-spectrum antitumor activity demonstrated for telomerase promoter-driven therapeutic virus

MLN-341 and MLN-581 granted fast track designation

Potential therapeutic benefit of inhibitors of the MAPK pathway in lung diseases

Zambon licenses Vectura's PowderHale technology for dry powder inhaler product

TH-9507 improves immune function in the elderly

Esteve invests in HemispheRx

FDA approves Ritalin LA for ADHD

Oxford BioMedica adds Repoxygen for anemia to development portfolio

American Biogenetic Sciences seeks partners for oral smallpox vaccine

Domantis receives E.U. grant for domain antibody research

Omapatrilat superior to enalapril in patients with systolic hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...